AMRI’s New York site picked for NExT cancer program

New York
New York

Contract research and manufacturing services provider AMRI ($AMRI) has seen its Buffalo, NY, site selected to participate as a Dedicated Chemical Biology Consortium Center for the Experimental Therapeutics (NExT) Program, centered at the Frederick National Laboratory for Cancer Research.

The Frederick National Lab--sponsored by the National Cancer Institute--is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology.

AMRI said in a release that it is participating in the consortium via a research subcontract from Leidos Biomedical Research--a prime contractor for the national lab.

The Chemical Biology Consortium is the discovery engine for the NCI Experimental Therapeutics (NExT) Program and is focused on advancing cancer meds against new molecular and genetic cancer targets.

AMRI's Buffalo facility will under the pact provide a variety of drug discovery services to the consortium for a period of 5 years, the company said.

“Being selected as a dedicated center for the NExT program is a reflection of AMRI's commitment and strength as a partner for oncology drug development,” said Christopher Conway, senior vice president of discovery and development services at AMRI.

“Our integrated drug discovery facility in Buffalo combines multiple scientific disciplines, state of the art technologies, and the capabilities to advance from compound discovery through pharmaceutical product manufacturing--all under one roof.

“This accelerates drug development by promoting cross-disciplinary collaboration, enabling faster transfer of data and providing partners with greater access via single points of contact. This is especially valuable in oncology drug development, where there is a tremendous emphasis for drug researchers to pursue new and more complex avenues of cancer drug development.”

It's been a good few months for AMRI after acquiring Euticals in a $358 million deal in May, beefing up its API offering.

Meanwhile in February, it hailed a "transformative year" as it posted a set of strong financials for 2015 that saw sales jump by 45%, as the company looks to delve more deeply into research and manufacturing services.

-check out the release

Related Articles:
AMRI to acquire Euticals in a $358M deal, beefing up API offering
AMRI scores a revenue jump after a spate of deals